Literature DB >> 12751041

Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.

Ronald J Ellis1, Meredith E Childers, Joshua D Zimmerman, Simon D W Frost, Reena Deutsch, J Allen McCutchan.   

Abstract

To characterize, over time, cerebrospinal fluid (CSF) virus-load change in clinically stable patients, human immunodeficiency virus (HIV)-1 RNA levels were measured in serial CSF samples and in plasma samples obtained, during periods of 20 days-6 years, from 17 HIV-infected individuals not receiving antiretroviral treatment. Longitudinal trends were analyzed by linear regression and restricted maximum-likelihood techniques. CSF HIV-1 RNA levels varied within a restricted range (+/-0.5 log(10) copies/mL) around each subject-specific mean. Although 16 of the 17 subjects had CSF slopes not significantly different from zero, slopes that were more positive were associated with lower CD4 counts. In an individual patient, a CSF virus-load change >0.5 log(10) copies/mL may be clinically significant. Furthermore, our data suggest that, if the CSF virus load reflects the size of the reservoir of infected cells in the central nervous system, this reservoir may increase in those individuals with advanced immunosuppression but is stable, over several years, in patients without AIDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751041     DOI: 10.1086/375152

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Authors:  Jose A Muñoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugènia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence.

Authors:  David J Moore; Carolina Posada; Mili Parikh; Miguel Arce; Florin Vaida; Patricia K Riggs; Ben Gouaux; Ronald J Ellis; Scott L Letendre; Igor Grant; J Hampton Atkinson
Journal:  AIDS Behav       Date:  2012-11

3.  Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

Authors:  David Croteau; Scott Letendre; Brookie M Best; Ronald J Ellis; Sheila Breidinger; David Clifford; Ann Collier; Benjamin Gelman; Christina Marra; Gilbert Mbeo; Allen McCutchan; Susan Morgello; David Simpson; Lauren Way; Florin Vaida; Susan Ueland; Edmund Capparelli; Igor Grant
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1.

Authors:  Adrian Lupescu; C-Thomas Bock; Philipp A Lang; Susanne Aberle; Heike Kaiser; Reinhard Kandolf; Florian Lang
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.

Authors:  Gabriele Arendt; Thorsten Nolting; Christian Frisch; Ingo-Wilhelm Husstedt; Nora Gregor; Eleni Koutsilieri; Mattias Maschke; Alexander Angerer; Mark Obermann; Eva Neuen-Jacob; Ortwin Adams; Sabine Loeffert; Peter Riederer; Volker ter Meulen; Sieghart Sopper
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

6.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.